- AstraZeneca and Merck said the European Commission had approved ovarian cancer drug as a front-line therapy following positive clinical trial results.

The European Commission approval was based on data from the pivotal Phase III SOLO-1 trial which tested the cancer drug, Lynparza, as maintenance monotherapy compared with placebo in patients with advanced ovarian cancer following 1st-line platinum-based chemotherapy.

The Phase III SOLO-1 trial showed that 60% of patients receiving the cancer drug Lynparza remained free of disease progression after three years compared with just 27% on placebo.

This approval sets the stage for a new standard of care in the EU for women with ovarian cancer and a BRCA mutation,' said Dave Fredrickson, Executive Vice President, Oncology Business Unit.

'SOLO-1, Lynparza demonstrated clinically-meaningful results with a 70% reduction in the risk of disease progression or death in the first-line maintenance treatment of patients with BRCAm advanced ovarian cancer,' said Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories.

Story provided by